RA Capital Management, LLC, a Boston, MA-based venture capital firm, closed its inaugural fund, at just over $300m.
RA Capital Nexus Fund, L.P., which boosts RA Capital’s private deal capacity to nearly $1 billion and total assets under management to approximately $2.5 billion, is expected to participate in substantially all investments in private companies made by RA Capital alongside its main, longstanding fund, RA Capital Healthcare Fund L.P.
Founded in 2012, RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. It provides seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation from inception through commercialization. It has made over 100 private company investments
The internal incubator and a venture partner/executive-in-residence program are designed to support company creation efforts. The incubator currently has 19 programs in discovery and early development and works to advance them in a time- and cost-efficient manner. To date, two companies have been launched with drug candidates based on molecules initially discovered and developed in the incubator. The venture partner and executive-in-residence programs bring in experienced executives and entrepreneurs who help to build and lead new companies.
The firm’s investment process is led by RA Capital’s Managing Director group, which includes Portfolio Managers Peter Kolchinsky and Raj Shah, Co-Heads of Venture Josh Resnick and Andrew Levin, and nine other professionals.
Nexus is a natural extension of RA Capital’s investment strategy, expanding the private capital pool to enable RA Capital to take larger positions in high-conviction investments and opening the RA Capital platform to limited partners who prefer investing in a closed-end venture fund.